vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and ENANTA PHARMACEUTICALS INC (ENTA). Click either name above to swap in a different company.
ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $9.4M, roughly 2.0× Broadway Financial Corp). Broadway Financial Corp runs the higher net margin — 1934.0% vs -64.1%, a 1998.1% gap on every dollar of revenue. On growth, Broadway Financial Corp posted the faster year-over-year revenue change (10.1% vs 9.8%). Broadway Financial Corp produced more free cash flow last quarter ($-13.0K vs $-11.8M). Over the past eight quarters, Broadway Financial Corp's revenue compounded faster (9.7% CAGR vs 4.5%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
BYFC vs ENTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.4M | $18.6M |
| Net Profit | $1.0M | $-11.9M |
| Gross Margin | — | — |
| Operating Margin | — | -60.5% |
| Net Margin | 1934.0% | -64.1% |
| Revenue YoY | 10.1% | 9.8% |
| Net Profit YoY | -21.8% | 46.4% |
| EPS (diluted) | $0.02 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | $18.6M | ||
| Q3 25 | $9.0M | $15.1M | ||
| Q2 25 | $8.1M | $18.3M | ||
| Q1 25 | $8.3M | $14.9M | ||
| Q4 24 | $8.6M | $17.0M | ||
| Q3 24 | $8.7M | $14.6M | ||
| Q2 24 | $8.2M | $18.0M | ||
| Q1 24 | $7.8M | $17.1M |
| Q4 25 | $1.0M | $-11.9M | ||
| Q3 25 | $-23.9M | $-18.7M | ||
| Q2 25 | $752.0K | $-18.3M | ||
| Q1 25 | $-2.7M | $-22.6M | ||
| Q4 24 | $1.3M | $-22.3M | ||
| Q3 24 | $516.0K | $-28.8M | ||
| Q2 24 | $256.0K | $-22.7M | ||
| Q1 24 | $-154.0K | $-31.2M |
| Q4 25 | — | -60.5% | ||
| Q3 25 | -256.2% | -121.6% | ||
| Q2 25 | 12.8% | -103.2% | ||
| Q1 25 | -45.3% | -164.3% | ||
| Q4 24 | 21.7% | -138.8% | ||
| Q3 24 | 8.5% | -204.4% | ||
| Q2 24 | 4.8% | -134.6% | ||
| Q1 24 | -2.9% | -192.1% |
| Q4 25 | 1934.0% | -64.1% | ||
| Q3 25 | -264.2% | -123.6% | ||
| Q2 25 | 9.3% | -99.7% | ||
| Q1 25 | -32.3% | -151.7% | ||
| Q4 24 | 15.3% | -131.4% | ||
| Q3 24 | 5.9% | -197.3% | ||
| Q2 24 | 3.1% | -126.1% | ||
| Q1 24 | -2.0% | -182.7% |
| Q4 25 | $0.02 | $-0.42 | ||
| Q3 25 | $-2.86 | $-0.88 | ||
| Q2 25 | $0.00 | $-0.85 | ||
| Q1 25 | $-0.39 | $-1.06 | ||
| Q4 24 | $0.07 | $-1.05 | ||
| Q3 24 | $-0.03 | $-1.36 | ||
| Q2 24 | $0.02 | $-1.07 | ||
| Q1 24 | $-0.02 | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $37.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $262.8M | $126.6M |
| Total Assets | $1.3B | $329.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | $37.4M | ||
| Q3 25 | $19.7M | $32.3M | ||
| Q2 25 | $29.5M | $44.8M | ||
| Q1 25 | $15.8M | $60.2M | ||
| Q4 24 | $61.4M | $84.3M | ||
| Q3 24 | $97.1M | $37.2M | ||
| Q2 24 | $89.8M | $35.8M | ||
| Q1 24 | $67.1M | $63.5M |
| Q4 25 | $262.8M | $126.6M | ||
| Q3 25 | $261.7M | $64.7M | ||
| Q2 25 | $284.7M | $79.3M | ||
| Q1 25 | $283.6M | $93.5M | ||
| Q4 24 | $285.0M | $111.8M | ||
| Q3 24 | $286.2M | $128.8M | ||
| Q2 24 | $282.1M | $148.9M | ||
| Q1 24 | $281.1M | $166.1M |
| Q4 25 | $1.3B | $329.5M | ||
| Q3 25 | $1.3B | $280.7M | ||
| Q2 25 | $1.2B | $301.0M | ||
| Q1 25 | $1.3B | $323.0M | ||
| Q4 24 | $1.3B | $348.6M | ||
| Q3 24 | $1.4B | $376.7M | ||
| Q2 24 | $1.4B | $398.8M | ||
| Q1 24 | $1.4B | $413.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $-11.7M |
| Free Cash FlowOCF − Capex | $-13.0K | $-11.8M |
| FCF MarginFCF / Revenue | -0.1% | -63.6% |
| Capex IntensityCapex / Revenue | 2.6% | 0.8% |
| Cash ConversionOCF / Net Profit | 0.22× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | $-18.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | $-11.7M | ||
| Q3 25 | $3.8M | $-6.5M | ||
| Q2 25 | $3.0M | $17.5M | ||
| Q1 25 | $-4.3M | $-13.5M | ||
| Q4 24 | $1.4M | $-16.8M | ||
| Q3 24 | $6.1M | $-10.4M | ||
| Q2 24 | $9.8M | $-14.8M | ||
| Q1 24 | $-11.7M | $-28.6M |
| Q4 25 | $-13.0K | $-11.8M | ||
| Q3 25 | $3.7M | $-7.9M | ||
| Q2 25 | $3.0M | $17.4M | ||
| Q1 25 | $-4.4M | $-16.0M | ||
| Q4 24 | $1.3M | $-25.5M | ||
| Q3 24 | $6.1M | $-19.4M | ||
| Q2 24 | $9.7M | $-21.3M | ||
| Q1 24 | $-11.7M | $-30.3M |
| Q4 25 | -0.1% | -63.6% | ||
| Q3 25 | 41.1% | -52.5% | ||
| Q2 25 | 37.0% | 94.7% | ||
| Q1 25 | -52.4% | -107.4% | ||
| Q4 24 | 14.7% | -150.6% | ||
| Q3 24 | 69.6% | -132.5% | ||
| Q2 24 | 118.9% | -118.6% | ||
| Q1 24 | -149.7% | -177.5% |
| Q4 25 | 2.6% | 0.8% | ||
| Q3 25 | 1.2% | 9.6% | ||
| Q2 25 | 0.2% | 0.8% | ||
| Q1 25 | 0.2% | 17.0% | ||
| Q4 24 | 1.6% | 51.6% | ||
| Q3 24 | 0.3% | 61.3% | ||
| Q2 24 | 0.5% | 36.4% | ||
| Q1 24 | 0.7% | 9.8% |
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 11.85× | — | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
